| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| SCYX | SCYX | Shares | USD | XNCM |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| SCYX | SCYX | Shares | USD | XNCM |
Scynexis, Inc. develops therapies for severe rare diseases, focusing on addressing unmet medical needs. The company is advancing SCY-770, a direct AMPK activator for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), and SCY-247, a second-generation fungicide targeting antimicrobial-resistant fungal infections. Scynexis operates in the biopharmaceutical sector, primarily serving patients with progressive and underserved conditions.
No recent RNS announcements for SCYX across SCYX.
No recent RNS announcements for SCYX across SCYX.